Rethinking Antibiotic Prophylaxis in Surgery / Nehad Jaser Ahmed
Rethinking Antibiotic Prophylaxis in Surgery
Nehad Jaser Ahmed
Surgical site infections (SSIs) remain a major healthcare
concern, increasing hospital stays, costs, and patient complications. Although
antibiotic prophylaxis is essential for preventing SSIs, the choice of
antibiotic is critical. In recent years, broader-spectrum cephalosporins such
as ceftriaxone have been increasingly used, often without strong evidence that
they provide superior protection compared to narrower options like cefazolin.
Across multiple large-scale analyses, the findings were
consistent:
- Cefazolin
is as effective as broader-spectrum cephalosporins (e.g., cefuroxime,
ceftriaxone) in preventing SSIs across clean, clean-contaminated, and
contaminated surgeries.
- Broader-spectrum
antibiotics do not reduce infection rates compared to cefazolin.
- Overuse
of broad-spectrum agents remains common in real-world surgical practice.
- Such
overuse increases antimicrobial resistance risk, costs, and unnecessary
drug exposure.
Importantly, when antimicrobial stewardship programs were
implemented—through guideline enforcement, education, and prescription
review—significant improvements were observed:
- More
appropriate antibiotic selection
- Better
timing and duration of prophylaxis
- Reduced
antibiotic consumption
- Lower
SSI rates
- Decreased
healthcare costs
Overall, the combined evidence demonstrates that smarter
antibiotic selection—not broader coverage—is key to effective surgical
infection prevention. Cefazolin remains a reliable, cost-effective
first-line option, and stewardship programs play a crucial role in aligning
clinical practice with evidence-based recommendations.
The central message is clear: improving surgical outcomes
does not require stronger antibiotics, but rather appropriate, evidence-based
use.
تعليقات
إرسال تعليق